-+ 0.00%
-+ 0.00%
-+ 0.00%

Jaguar Health plans AI platforms to advance crofelemer clinical development for intestinal failure

PUBT·04/13/2026 12:32:25
Listen to the news
Jaguar Health plans AI platforms to advance crofelemer clinical development for intestinal failure
  • Jaguar Health plans to use artificial intelligence platforms to support development and anticipated commercialization of crofelemer for intestinal failure indications in adult and pediatric patients.
  • Program focus includes pediatric microvillus inclusion disease, an ultrarare disorder with no available treatments and high mortality risk.
  • Clinical results have already been presented from an investigator-sponsored MVID treatment program, indicating consistent clinical benefit without disclosing detailed metrics.
  • Jaguar expects its MVID development plan to include pursuit of FDA Breakthrough Therapy designation in coming months to speed regulatory pathways.
  • Company is in business development discussions aimed at securing non-dilutive funding to advance crofelemer programs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604130830ACCESSWRNAPR_____1156912) on April 13, 2026, and is solely responsible for the information contained therein.